CAR

14 registered clinical trials studyying CAR — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treat NCT07283315	The Children's Hospital of Zhejiang University School of Medicine	EARLY_Phase 1
Unknown	ThisCART19A Bridging to alloHSCT for R/R B-ALL NCT05679687	The First Affiliated Hospital of Soochow University	Phase 1
Unknown	ThisCART19A for B-NHL Relapsed After Auto-CAR T NCT05691153	The First Affiliated Hospital of Soochow University	Phase 1
Unknown	Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage NCT05429905	KK Women's and Children's Hospital	Phase 1 / Phase 2
Recruiting	CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lym NCT05648019	KK Women's and Children's Hospital	Phase 2
Recruiting	CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic NCT05043571	National University Hospital, Singapore	Phase 1
Unknown	TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia NCT05017883	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	N/A
Recruiting	ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia. NCT05038696	National University Hospital, Singapore	Phase 1
Unknown	CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors NCT04702841	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	EARLY_Phase 1
Unknown	TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia NCT04692948	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	N/A
Unknown	CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors NCT04691713	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	N/A
Unknown	CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malign NCT04700319	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	EARLY_Phase 1
Recruiting	GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression NCT03198546	Second Affiliated Hospital of Guangzhou Medical University	Phase 1
Unknown	Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. NCT03267173	First Affiliated Hospital of Harbin Medical University	EARLY_Phase 1